Physician profile
Anas Renno
NPI 1356751697
$2,124.50
in general payments reported to CMS, 2019-2025
17 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.19 · 2020: $12.65 · 2021: $13.26 · 2022: $32.44 · 2023: $343 · 2024: $552 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.48 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.38 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.54 | 2023-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $245.78 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $230.68 | 2022-2025 | Entyvio, Eohilia |
| Lumendi LLC | $224.48 | 2025 | |
| Phathom Pharmaceuticals, INC. | $157.81 | 2024-2025 | Voquezna |
| Genzyme Corporation | $134.28 | 2024-2025 | |
| Ardelyx, INC. | $89.61 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $79.23 | 2024-2025 | Vowst, Zenpep |
| Lilly USA, LLC | $67.96 | 2021-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $66.83 | 2024-2025 | Dupixent |
| Braintree Laboratories, INC. | $56.85 | 2024-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $38.46 | 2024 | Resmetirom |
| Intercept Pharmaceuticals, INC. | $34.79 | 2019-2025 | |
| Qol Medical, LLC | $16.69 | 2025 | Sucraid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.65 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Renno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.